Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Orforglipron

A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight

Eli Lilly · Phase 1 · Completed · Enrollment 533

NCT06440980

ArmPopulationDoseWeeksEstimandWeight change
Part A: LY3502970 QD Oral Administration (Cohort 1A, Sequence 1)Obesity or overweightn/r22n/rn/r
Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 2)Obesity or overweightn/r22n/rn/r
Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 3)Obesity or overweightn/r22n/rn/r
Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 4)Obesity or overweightn/r22n/rn/r
Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 1)Obesity or overweightn/r22n/rn/r
Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 2)Obesity or overweightn/r22n/rn/r
Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 3)Obesity or overweightn/r22n/rn/r
Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 4)Obesity or overweightn/r22n/rn/r
Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 1)Obesity or overweightn/r22n/rn/r
Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 2)Obesity or overweightn/r22n/rn/r
Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 3)Obesity or overweightn/r22n/rn/r
Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 1)Obesity or overweightn/r22n/rn/r
Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 2)Obesity or overweightn/r22n/rn/r
Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 3)Obesity or overweightn/r22n/rn/r